A Randomized Double-blind, Four-Arm Active and Placebo-controlled Dose-Finding Trial to Evaluate the Efficacy, Tolerability, Safety and Dose Response of LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 18 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Deupirfenidone (Primary) ; Pirfenidone
Indications Idiopathic pulmonary fibrosis
Focus Registrational; Therapeutic Use
Acronyms ELEVATE
Sponsors PureTech Health

Most Recent Events

16 Dec 2024 According to a PureTech Health Media Release, Additional data from this trial will be presented at a future forum.
16 Dec 2024 According to a PureTech Health Media Release, Company to host a webcast and conference call today at 9:00am EST / 2:00pm GMT.
16 Dec 2024 Primary endpoint (Rate of decline in Forced Vital Capacity over 26 weeks (Part A)) has been met, according to PureTech Health Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight